Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00111631 · ClinicalTrials.gov registry record · Phase 2
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 218
- Enrollment target
NCT00111631: Completed Phase 2 study, sponsored by Hoffmann-La Roche.
NCT00111631 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 218 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00111631, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 218 participants
- Enrollment target
Study Summary
This study will assess the efficacy, safety and tolerability of DPP-IV Inhibitor in patients with type 2 diabetes receiving a stable dose of metformin. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.
Interventions
- DRUG Placebo
- DRUG Metformin
- DRUG DPP-IV Inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2005-05 |
| Est. Completion | 2006-10 |
| Phase | Phase 2 |
What the finished NCT00111631 record still lists
NCT00111631 is an interventional study that assigns participants to a tested intervention. The registered 218 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00111631 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00111631 about?
NCT00111631 is a clinical study titled "A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes". This study will assess the efficacy, safety and tolerability of DPP-IV Inhibitor in patients with type 2 diabetes receiving a stable dose of metformin. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.
What is the current status of trial NCT00111631?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 218 participants. The study started on 2005-05. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00111631?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), DPP-IV Inhibitor (DRUG).
Who is sponsoring clinical trial NCT00111631?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00111631's enrollment target sits among peer trials
218 284th of 2000 higher than 1,715 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04693858 · 218 participants · NA
Efficacy Trial of the CALM Intervention
- NCT05909202 · 218 participants · NA
A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients
- NCT06000761 · 218 participants · NA
Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit
- NCT06249126 · 218 participants · NA
Primary Subtalar Arthrodesis for Calcaneal Fractures
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia